We describe the case of a 36-year-old woman with a history of vitiligo who presented with an insidious onset of neurologic, vestibular, ocular, and auditory symptoms. She had recently noted the onset of vertigo, tinnitus, and hypersensitivity to sound. Findings on audiometry were within normal limits, although the patient reported some auditory discomfort during the testing. The patient had a history of bilateral uveitis and peripheral neurologic symptoms. She was diagnosed with Vogt-Koyanagi-Harada (VKH) syndrome and started on corticosteroid therapy. Her neurologic, vestibular, ocular, and auditory symptoms resolved. VKH syndrome is an uncommon cause of vertigo and hearing loss, but it should be considered in the differential diagnosis of patients with autoimmunity-related inner ear symptoms.
Introduction
Vogt-Koyanagi-Harada (VKH) syndrome is a granulomatous bilateral uveitis associated with integumentary, neurologic, and auditory findings. It is believed to be caused by T-cell-mediated autoimmunity directed against melanocytes, and therefore it can clinically affect all organ systems that contain these cells. VKH syndrome has primarily been described in the ophthalmology literature because the primary pathologic findings are bilateral uveitis and destruction of melanocytes in the retina.
We report the case of a 36-year-old woman who presented to our otolaryngology clinic with symptoms of vertigo, tinnitus, and hyperacusis after she had been assessed for bilateral uveitis and additional systemic complaints. This case highlights the importance of otolaryngologists' awareness of VKH syndrome and its optimal management strategies.
Case report
A 36-year-old woman presented to the otolaryngology clinic with complaints of vertigo, tinnitus, and hyperacusis. The vertigo would last for approximately 2 minutes, and it was relieved when the patient laid down. These episodes would occur approximately three times per week following exertion. They were not directly related to movements of the head.
The tinnitus was also episodic, and it occurred without warning and without any noticeable precipitating factors. It was bilateral and unrelated to the episodes of vertigo. The patient denied any subjective hearing loss, but given her tinnitus, she had been sent for audiometry before being seen in the otolaryngology clinic.
The patient's medical history was significant for a diagnosis of bilateral uveitis and an episode of acute-onset meningeal signs, including headache and nuchal rigidity, which was associated with peripheral paresthesias. These events had occurred immediately before the onset of her vertiginous symptoms. She denied any history of ocular trauma and other head trauma. Her uveitis was being treated with 80 mg/day of prednisone; upon the initiation of this therapy, her vertiginous episodes seemed to lessen. She also had a history of vitiligo since childhood; the vitiligo was marked by varying periods of alopecia.
Findings on the head and neck examination were within normal limits. A dermatologic examination revealed evidence of diffuse alopecia and vitiligo over areas of the scalp. The Dix-Hallpike maneuver was negative for vertigo and nystagmus. A neurologic examination detected no balance or cranial nerve deficits. Screening audiometric examination revealed normal hearing in both ears and type A tympanic membranes. The audiogram included a note from the audiologist that the patient had experienced a sensation of subjective hyperacusis during the examination.
Laboratory investigations, including the erythrocyte sedimentation rate and measurement of C-reactive protein, were negative for autoimmune serologies. Unfortunately, these laboratory tests had been performed after the patient had already been started on corticosteroid therapy by her ophthalmologist. Therefore, the true level of these inflammatory markers prior to therapy was unknown. As part of the autoimmunity workup, the patient underwent HLA-DR subtyping and was found to carry the HLA-DR4 subtype.
Together, this patient's symptom complex and response to prednisone suggested a diffuse autoimmune process such as VKH syndrome, sarcoidosis, multiple sclerosis, systemic lupus erythematosus, Cogan syndrome, or another systemic vasculitis such as polyarteritis nodosa.
The patient was subsequently evaluated in the neurology and rheumatology departments. As a result of discussions with these specialists and with the patient's ophthalmologist, she was found to meet all the criteria for a diagnosis of complete VKH. She subsequently required intermittent courses of corticosteroids to control temporary flares in her ocular symptom complex, but she did not require any long-term immunomodulating therapy.
Discussion
VKH syndrome is a systemic autoimmune disease in which T cells are activated to respond to melanocytes. Therefore, multiple organ systems are affected. The criteria necessary for the diagnosis of VKH syndrome were recently redefined by Kitamura et al. 1 A diagnosis of VKH requires that the patient have bilateral ocular involvement (such as acute choroiditis, uveitis, retinal detachment, or pigment changes) or late findings indicative of previous ocular involvement (such as the sunset glow fundus, chorioretinal depigmentation, etc.).
Neurologic and auditory findings-including meningismus, tinnitus, or cerebrospinal fluid pleocytosis detected through lumbar puncture-must also be present. The final piece necessary for the diagnosis is the presence of integumentary changes such as alopecia, vitiligo, and poliosis. Patients with a history of ocular trauma or other ocular disease are excluded. 1 Given that the criteria for diagnosis can be met on clinical grounds, our patient was diagnosed with complete VKH syndrome despite the lack of autoimmune serologic findings or inflammatory markers. Incomplete VKH syndrome is characterized by ocular findings with either neurologic or integumentary changes, and probable VKH syndrome is associated with ocular manifestations only.
Given the symptoms of a typical presentation, it is important for the otolaryngologist to be aware of VKH syndrome. While much research continues to be performed on the etiology of this peculiar entity, the pathophysiology is thought to involve a T-cell-mediated autoimmunity toward melanocytes in all organs. 2 The otolaryngologic manifestations of this illness are a direct result of the involvement of the melanocytes present in the cochlea and semicircular canals (the intermediate cells of the stria vascularis). A loss of these cells as a result of a T-cell attack might have caused the symptoms seen in our patient.
Patients with vertiginous manifestations of VKH syndrome typically present with episodes of transient true vertigo similar to those seen in Ménière disease. They also usually exhibit evidence of horizontal jerk nystagmus. 3 Tinnitus may be either episodic, as in our patient, or constant. The additional finding of sensorineural hearing loss may make the distinction between VKH syndrome and Ménière disease difficult, but an association with multiple other systemic findings would make Ménière disease less likely. According to Ondrey et al, the sensorineural hearing loss with VKH syndrome is generally of mild to moderate severity (20 to 59 dB) in the high-frequency range. 4 VKH syndrome is a relatively rare disorder. Its greatest incidence is seen in women aged 20 to 50 years. 4 With regard to its pathophysiology, it is not surprising that this disease is more common in patients with Native American, Hispanic, Asian, and Middle East ancestry, given the increased pigmentation seen in people with these ethnic and racial backgrounds. It is interesting to note that our patient reported a distant Native American ancestry.
VKH syndrome is also associated with HLA-DR4, specifically the DRB1*0405 allele. The presence of this allele in patients with VKH syndrome places them at higher risk for chronic disease. Our patient was found to carry the HLA-DR4 subtype, but she did not possess the DRB1*0405 allele.
The standard treatment for patients with VKH syn-drome is corticosteroid therapy. Patients are typically started on high-dose prednisone (1 to 2 mg/kg/day for at least 6 months) and monitored for treatment response with frequent ocular examinations. Sensorineural hearing loss has been found to be partially reversible following corticosteroid treatment. 4 Pelosi and Chandrasekhar recently reported a case in which they used intratympanic steroids with resulting improvement in their patient's hearing thresholds. 5 The long-term vestibular and auditory functions following corticosteroid treatment have not been well studied; our patient reported a full resolution of her vertigo and tinnitus after treatment. She declined vestibular testing, and while her preliminary examination was negative, it is unknown whether she possessed any minor residual vestibular deficits.
Additional treatment options are desirable, given the morbidity associated with corticosteroid treatment. Some options that have been studied include azathioprine, cyclosporine, various monoclonal antibodies, and interferon alfa. However, interferon alfa has been associated with some negative ocular effects, and further study of these and other therapies is necessary. [6] [7] [8] The prognosis for patients with VKH syndrome varies. While early intervention with corticosteroids may result in a complete resolution for some patients, others may develop a more chronic disease characterized by flares and relapses. The long-term effect that VKH syndrome has on visual acuity is difficult to determine, given the ocular morbidity associated with long-term corticosteroid treatment. Ocular complications include cataract, glaucoma, choroidal neovascular membranes, and subretinal fibrosis. Factors that affect the risk of developing these complications include the number of disease relapses, the patient's age, and the patient's visual acuity at the time of presentation. 9 At this point, VKH syndrome has been discussed primarily in the ophthalmology literature. However, the constellation of symptoms typically associated with this disease includes many that are seen in otolaryngology practice, and it is therefore important for otolaryngologists to be aware of this clinical entity. Despite its relative rarity, it should still be considered in the differential diagnosis of patients who present with vertigo, tinnitus, sensorineural hearing loss, or hyperacusis for which an autoimmune etiology is suspected. In addition, given the lack of clinical research into the nonocular manifestations of VKH syndrome, it is important for further research to be undertaken so that affected patients can be optimally managed for their nonocular symptoms.
